Validation of the patient health questionnaire (PHQ)-9 and PHQ-2 in patients with COPD in China

在中国慢性阻塞性肺疾病患者中验证患者健康问卷(PHQ)-9和PHQ-2

阅读:1

Abstract

BACKGROUND: Patient Health Questionnaire (PHQ-9) and PHQ-2 are commonly used screening tools for depression but have not been validated in Chronic obstructive pulmonary disease (COPD) patients. We aimed to validate PHQ-9 and PHQ-2 among COPD patients in China. METHODS: Stable COPD patients were assessed using a PHQ-9 questionnaire and then assessed by a senior psychiatrist to confirm the diagnosis of major depressive disorder (MDD) according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Receiver operating characteristic curve analysis was performed to validate the PHQ-9/PHQ-2. RESULTS: Out of 265 COPD patients, 11.7% were diagnosed with MDD. The Cronbach's α-coefficient for PHQ-9 was 0.751. Both PHQ-9 and PHQ-2 showed good correlations with COPD symptoms and quality of life. The AUC values of PHQ-9 and PHQ-2 were 0.848 and 0.736, respectively, for identifying MDD. Based on the highest Youden index, the optimal cut-off scores were PHQ-9 ≥ 7 and PHQ-2 ≥ 2, with a sensitivity of 74.2% and 58.1% and specificity of 89.7% and 89.3%, respectively. CONCLUSION: PHQ-9 score ≥ 7 and PHQ-2 score ≥ 2 should be used as the optimal cut-offs for COPD patients in China. PHQ-9 is a valid tool for detecting MDD in COPD patients, while PHQ-2 (score < 2) is more useful for quickly excluding MDD.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。